STANDIGM TO ATTEND BIO-EUROPE® 2022
CAMBRIDGE, England, Oct. 18, 2022 /PRNewswire/ -- Standigm, the workflow AI-driven drug discovery company, today announced that it will be represented at the 28th annual BIO-Europe taking place October 24–26, 2022 in Leipzig, Germany. After being delivered digitally over the last two years, the event is expected to bring together over 4,000 executives from biotech, pharma and finance companies to engage in 27,000+ one-to-one meetings.
- CAMBRIDGE, England, Oct. 18, 2022 /PRNewswire/ -- Standigm , the workflow AI-driven drug discovery company, today announced that it will be represented at the 28th annual BIO-Europe taking place October 2426, 2022 in Leipzig, Germany.
- Standigm business development (BD) team and Standigm UK members including CBO Carl Foster will be attending, presenting the company profile, AI technologies and AI-driven pipelines.
- "We are excited to be providing an inside look into Standigm at the upcoming BIO-Europe Conference and are looking forward to having meaningful partner discussions," said Jinhan Kim, CEO and Co-founder of Standigm.
- Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK for novel target discovery and Standigm BEST for novel compound generation.